Comparison of presenting features and three-year disease course in Turkish patients with Behçet uveitis who presented in the early 1990s and the early 2000s

Ocular Immunology and Inflammation

Volumn 20, Issue 6, 2012, Pages 423-428

  Cingu, Abdullah Kursat ^a   Onal, Sumru ^b   Urgancioglu, Meri ^c   Tugal Tutkun, Ilknur ^c  

^a DICLE UNIVERSITY   (Turkey)

^b AMERICAN HOSPITAL   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Beh et uveitis; Immunomodulatory treatment; Interferon alfa 2a; Prognosis; Visual outcome

Indexed keywords

ALPHA2A INTERFERON; AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOMODULATING AGENT; INFLIXIMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADULT; ARTICLE; BEHCET DISEASE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; TURKEY (REPUBLIC); VISUAL ACUITY;

ADOLESCENT; ADULT; AGED; BEHCET SYNDROME; CHILD; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INTERFERON-ALPHA; MALE; MIDDLE AGED; PROGNOSIS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TIME FACTORS; TURKEY; UVEITIS; VISUAL ACUITY; YOUNG ADULT;

EID: 84870878957     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2012.713159     Document Type: Article

References (26)

1. Behçet H. Über rezidivierende aphthose, durch ein Virus verursachte Geschwüre am Mund, am Auge und an den Genitalien. Dermatol Wochenschr. 1937;105:1152-1157.
2. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in Behçet disease: An analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373-380. (Pubitemid 39208563)
3. Yoshida A, Kawashima H, Motoyama Y, et al. Comparison of patients with Behçet's disease in the 1980s and 1990s. Ophthalmology. 2004;111(4):810-815. (Pubitemid 38429681)
4. International Study Group for Behçet's Disease. Evaluation of diagnostic ('classification') criteria in Behçet's disease: Toward internationally agreed criteria. Lancet. 1990;335(8697): 1078-1080.
5. Tugal-Tutkun I, Güney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behçet uveitis. Graefes ArchClinExpOphthalmol. 2006; 244(12):1692-1695. (Pubitemid 44830831)
6. Kitaichi N, Miyazaki A, Iwata D, et al. Ocular features of Behcet's disease: An international collaborative study. Br J Ophthalmol. 2007;91(12):1579-1582. (Pubitemid 350207374)
7. Kazokoglu H, Onal S, Tugal-Tutkun I, et al. Demographic and clinical features of uveitis in tertiary centers in Turkey. Ophthalmic Epidemiol. 2008;15(5):285-293.
8. Akiyama K, Numaga J, Yoshida A, et al. Statistical analysis of endogenous uveitis at Tokyo University Hospital. Jpn J Ophthalmol. 2006;50(1):69-71. (Pubitemid 43201040)
9. Wakabayashi T, Morimura Y, Miyamoto Y, et al. Changing patterns of intraocular inflammatory disease in Japan. Ocul Immunol Inflamm. 2003;11(4):277-286. (Pubitemid 38021423)
10. Kitamei H, Kitaichi N, Namba K, et al. Clinical features of intraocular inflammation in Hokkaido, Japan. Acta Ophthalmol. 2009;87(4):424-428.
11. Kotake S, Furudate N, Sasamoto Y, et al. Characteristics of endogenous uveitis in Hokkaido, Japan. Graefes Arch Clin Exp Ophthalmol. 1997;235:5-9. (Pubitemid 27029366)
12. Ando K, Fujino Y, Hijikata K, et al. Epidemiological features and visual prognosis of Behçet's disease. Jpn J Ophthalmol. 1999;43:312-317. (Pubitemid 29329392)
13. Shahram F, Davatchi F, Nadji A, et al. Recent epidemiological data on Behçet's disease in Iran: The 2001 survey. Adv Exp Med Biol. 2003;528:31-36. (Pubitemid 41582730)
14. Khairallah M, Attia S, Yahia SB, et al. Pattern of uveitis in Behçet's disease in a referral center inTunisia, North Africa. Int Ophthalmol. 2009;29(3):135-141.
15. Kump LI, Moeller KL, Reed GF, et al. Behçet's disease: Comparing 3 decades of treatment response at the National EyeInstitute. Can J Ophthalmol. 2008;43(4):468-472.
16. Taylor SR, Singh J, Menezo V, et al. Behçet disease: visual prognosis and factors influencing the development of visual loss. Am J Ophthalmol. 2011;152(6):1059-1066.
17. Kaçmaz RO, Kempen JH, Newcomb C, et al Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Group. Ocular inflammation in Behçet disease: Incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol. 2008;146(6):828-836.
18. Yu HG, Kim MJ, Oh FS. Fluorescein angiography and visual acuity in active uveitis with Behçet disease. Ocul Immunol Inflamm. 2009;17(1):41-46.
19. Demiroǧlu H, Barişta I, Dündar S. Risk factor assessment and prognosis of eye involvement in Behcet's disease in Turkey. Ophthalmology. 1997;104(4):701-705. (Pubitemid 27171995)
20. Kaburaki T, Araki F, Takamoto M, et al. Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Behçet's disease. Graefes Arch Clin Exp Ophthalmol. 2010;248(5):709-714.
21. Krause L, Köhler AK, Altenburg A, et al. Ocular involvement in Adamantiades-Behçet's disease in Berlin, Germany. Graefes Arch Clin Exp Ophthalmol. 2009;247(5):661-666.
22. Ambresin A, Tran VT, Spertini F, Herbort CP. Behçet's disease in Western Switzerland: Epidemiology and analysis of ocular involvement. Ocul Immunol Inflamm. 2002;10:53-63. (Pubitemid 36042847)
23. Chung YM, Yeh TS, Sheu MM, et al. Behcet's disease with ocular involvement in Taiwan: A joint survey of six major ophthalmological departments. J Formos Med Assoc. 1990;89(5):413-417.
24. Yang P, Fang W, Meng Q, et al. Clinical features of Chinese patients with Behçet's disease. Ophthalmology. 2008;115(2):312-318.
25. Muhaya M, Lightman S, Ikeda E, et al. Behcet's disease in Japan and in Great Britain: A comparative study. Ocul Immunol Inflamm. 2000;8:141-148. (Pubitemid 32002903)
26. Takeuchi M, Hokama H, Tsukahara R, et al. Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement. Graefes Arch Clin Exp Ophthalmol. 2005;243(11):1147-1152. (Pubitemid 43124166)